UNSPSC 51273930: Dextrose/lidocaine/tetracaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273930 Dextrose/lidocaine/tetracaine is a Commodity code that captures pharmaceutical products and medical supplies procured by state and local health agencies, though recent state and local opportunities tagged under this code actually span a broader mix of pharmaceutical procurement including naloxone, generic multi-source drugs, and over-the-counter products. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Work being solicited ranges from direct purchase of specific pharmaceutical products for community health initiatives to participation in multi-state pharmaceutical contracts and direct-to-manufacturer prescription programs designed to improve cost management and supply chain efficiency across government pharmacy benefit systems.

Recent activity appears concentrated in Florida and multistate cooperative arrangements. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building with an initial two-year term and one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (responses due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs for self-insured health plans, representing exploratory procurement design rather than a formal competitive solicitation.